Comparison
While FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38, Semax is used clinically in Russia for ischemic stroke and cognitive disorders; in models it improves learning, protects dopaminergic neurons, and modulates stress responses without significant endocrine ACTH-like effects166174.
While FOXO4-DRI works as a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38, Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), that is an analog of ACTH(4–10) with a Pro-Gly-Pro extension and exerts neurotrophic and neuroprotective actions partly via upregulation of BDNF and modulation of dopaminergic and glutamatergic systems40162165174.
FOXO4-DRI is amino acids long, whereas Semax is longer as it has a length of 7 amino acids. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset. Semax is made up of a sequence of Methionine, Glutamic acid, Histidine, Phenylalanine, Proline, Glycine, Proline.
FOXO4-DRI
Intracellular target is the FOXO4–p53 protein–protein interaction interface; it does not signal via a traditional cell-surface receptor38
Semax
Targets are not fully defined; interacts with melanocortin-related pathways and inhibits certain peptidases, but no single dominant receptor has been established174
FOXO4-DRI
FOXO4
Semax
POMC
No related articles are linked to these peptides yet.